EP3585420A4 - Peptides and methods of treating dystrophy-related disorders using the same - Google Patents

Peptides and methods of treating dystrophy-related disorders using the same Download PDF

Info

Publication number
EP3585420A4
EP3585420A4 EP18756867.0A EP18756867A EP3585420A4 EP 3585420 A4 EP3585420 A4 EP 3585420A4 EP 18756867 A EP18756867 A EP 18756867A EP 3585420 A4 EP3585420 A4 EP 3585420A4
Authority
EP
European Patent Office
Prior art keywords
peptides
methods
same
related disorders
dystrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18756867.0A
Other languages
German (de)
French (fr)
Other versions
EP3585420A2 (en
Inventor
Eytan R. Barnea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioIncept LLC
Original Assignee
BioIncept LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioIncept LLC filed Critical BioIncept LLC
Priority to EP22150813.8A priority Critical patent/EP4066850A3/en
Publication of EP3585420A2 publication Critical patent/EP3585420A2/en
Publication of EP3585420A4 publication Critical patent/EP3585420A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18756867.0A 2017-02-22 2018-02-22 Peptides and methods of treating dystrophy-related disorders using the same Withdrawn EP3585420A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22150813.8A EP4066850A3 (en) 2017-02-22 2018-02-22 Peptides and methods of treating dystrophy-related disorders using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762462292P 2017-02-22 2017-02-22
PCT/US2018/019279 WO2018156801A2 (en) 2017-02-22 2018-02-22 Peptides and methods of treating dystrophy-related disorders using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP22150813.8A Division EP4066850A3 (en) 2017-02-22 2018-02-22 Peptides and methods of treating dystrophy-related disorders using the same

Publications (2)

Publication Number Publication Date
EP3585420A2 EP3585420A2 (en) 2020-01-01
EP3585420A4 true EP3585420A4 (en) 2021-04-07

Family

ID=63253026

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18756867.0A Withdrawn EP3585420A4 (en) 2017-02-22 2018-02-22 Peptides and methods of treating dystrophy-related disorders using the same
EP22150813.8A Withdrawn EP4066850A3 (en) 2017-02-22 2018-02-22 Peptides and methods of treating dystrophy-related disorders using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP22150813.8A Withdrawn EP4066850A3 (en) 2017-02-22 2018-02-22 Peptides and methods of treating dystrophy-related disorders using the same

Country Status (6)

Country Link
EP (2) EP3585420A4 (en)
CN (1) CN110869044A (en)
AU (1) AU2018225163A1 (en)
CA (1) CA3054366A1 (en)
IL (1) IL268844A (en)
WO (1) WO2018156801A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160263186A1 (en) * 2013-10-22 2016-09-15 Bioincept, Llc Pif-transfected cells and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000151A (en) 2001-07-02 2005-06-06 Biolncept Inc New assays for preimplantation factor and preimplantation factor peptides.
US8222211B2 (en) 2001-07-02 2012-07-17 Bioincept, Llc Methods of administering PIF agonist peptides and uses thereof
US7723290B2 (en) * 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
US7723289B2 (en) 2003-10-22 2010-05-25 Bioincept, Llc PIF tetrapeptides
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
EP1793398A1 (en) 2005-12-05 2007-06-06 Sokymat Automotive GmbH Holding tool for fixing an electronic component and circular table manufacturing unit
JP5325092B2 (en) * 2006-03-13 2013-10-23 リアット・ミンツ Cachexia and / or anorexia and / or anorexia-ghrelin splice mutation to treat cachexia and / or malnutrition and / or lipodystrophy and / or muscle wasting and / or appetite-stimulation Use of the body
US8916532B2 (en) * 2008-04-28 2014-12-23 The Trustees Of The University Of Pennsylvania Methods for enhancing utrophin production via inhibition of microRNA
US8852940B2 (en) * 2009-04-01 2014-10-07 The Regents Of The University Of California Embryonic stem cell specific microRNAs promote induced pluripotency
MX371526B (en) 2011-05-27 2020-01-31 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives.
US9994617B2 (en) 2011-10-07 2018-06-12 Bicyclerd Limited Modulation of structured polypeptide specificity
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
EP2850095B1 (en) 2012-05-17 2019-10-09 RA Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
US20160250188A1 (en) * 2013-10-25 2016-09-01 Ernest D. Bush Methods for treatment of muscular dystrophies
US20170319645A1 (en) * 2014-09-16 2017-11-09 Bioincept, Llc Compositions and methods for treating acute radiation syndrome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160263186A1 (en) * 2013-10-22 2016-09-15 Bioincept, Llc Pif-transfected cells and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATRIZIA PESSINA ET AL: "Novel and optimized strategies for inducing fibrosis in vivo: focus on Duchenne Muscular Dystrophy", SKELETAL MUSCLE, BIOMED CENTRAL LTD, LONDON, UK, vol. 4, no. 1, 25 August 2014 (2014-08-25), pages 7, XP021193544, ISSN: 2044-5040, DOI: 10.1186/2044-5040-4-7 *
UTPAL BASU ET AL: "Translational Regulation of Utrophin by miRNAs", PLOS ONE, vol. 6, no. 12, 27 December 2011 (2011-12-27), pages e29376, XP055751401, DOI: 10.1371/journal.pone.0029376 *

Also Published As

Publication number Publication date
WO2018156801A2 (en) 2018-08-30
CN110869044A (en) 2020-03-06
IL268844A (en) 2019-10-31
EP4066850A2 (en) 2022-10-05
AU2018225163A1 (en) 2019-09-19
EP3585420A2 (en) 2020-01-01
EP4066850A3 (en) 2022-11-23
WO2018156801A3 (en) 2019-02-21
CA3054366A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
EP3634430A4 (en) Multibiotic agents and methods of using the same
EP3496666A4 (en) Devices and methods for the treatment of heart valve insufficiencies
EP3474785A4 (en) Spinal implant and methods of using the same
EP3538561A4 (en) Variant rna-guided polypeptides and methods of use
EP3720502A4 (en) Cytobiologics and therapeutic uses thereof
EP3442991A4 (en) Ras binding peptides and methods of use
EP3634442A4 (en) Methods for treating and preventing diseases
EP3684821A4 (en) Anti-hla-a2 antibodies and methods of using the same
EP3478723A4 (en) Pd-l1-specific antibodies and methods of using the same
EP3633034A4 (en) MODIFIED Cas9 PROTEIN AND USE THEREOF
EP3635418A4 (en) Power-outage-assessment apparatuses and methods
EP3436476A4 (en) Anti-ryk antibodies and methods of using the same
ZA201905851B (en) Peptides and methods for the treatment of diabetes
EP3651747A4 (en) Compositions and methods for the treatment of eye disorders
EP3558279A4 (en) Compositions and methods for the treatment of chronic pain
EP3635000A4 (en) Manabodies and methods of using
EP3525703A4 (en) Treatment devices and methods
EP3678701A4 (en) Therapeutic protein compositions and methods of making and using the same
EP3731867A4 (en) Anti-lrp5/6 antibodies and methods of use
EP3429584A4 (en) Compositions and methods for the treatment of presbyopia
EP3377085A4 (en) Peptides and methods of treating endometriosis using the same
EP3348273B8 (en) Compositions based on xyloglucan and proteins for the treatment of intestinal disorders
EP3554626A4 (en) Methods and devices for treating vascular related disorders
EP3419425A4 (en) Cooking devices and methods of using the same
EP3654964A4 (en) Composition and methods for the treatment of myopia

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190917

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40021181

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/10 20060101ALI20201127BHEP

Ipc: A61K 45/06 20060101ALI20201127BHEP

Ipc: A61K 38/04 20060101ALI20201127BHEP

Ipc: A61K 38/17 20060101ALI20201127BHEP

Ipc: A61K 38/08 20190101ALI20201127BHEP

Ipc: A61P 21/00 20060101ALI20201127BHEP

Ipc: A61K 38/19 20060101AFI20201127BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20210309

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/19 20060101AFI20210302BHEP

Ipc: A61K 38/10 20060101ALI20210302BHEP

Ipc: A61K 45/06 20060101ALI20210302BHEP

Ipc: A61K 38/17 20060101ALI20210302BHEP

Ipc: A61K 38/08 20190101ALI20210302BHEP

Ipc: A61K 38/04 20060101ALI20210302BHEP

Ipc: A61P 21/00 20060101ALI20210302BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220901